Payment overview · 2025
General Payments
$3,319.31
82 reported records · 25 companies
Healthcare provider profile · identity verified
Mark Conant, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · ST PETERSBURG, FL · NPI 1922431394
Verified facts
What the public records show
CMS Open Payments records show Mark Conant, M.D. received $3,319.31 in general payments during 2025 across 82 reported records.
Stryker Corporation accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $461.56 | 13.9% | 8 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $342.02 | 10.3% | 22 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $246.27 | 7.4% | 6 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $233.05 | 7.0% | 2 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $217.17 | 6.5% | 4 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $193.92 | 5.8% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $183.65 | 5.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $170.51 | 5.1% | 3 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $155.55 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $150.98 | 4.5% | 3 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $129.19 | 3.9% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $120.30 | 3.6% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $118.82 | 3.6% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $117.36 | 3.5% | 6 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $106.90 | 3.2% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $94.53 | 2.9% | 2 | 2025 |
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $66.61 | 2.0% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $41.85 | 1.3% | 2 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $35.49 | 1.1% | 2 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $24.85 | 0.8% | 1 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $24.23 | 0.7% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $23.47 | 0.7% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $21.67 | 0.7% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $20.09 | 0.6% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $19.27 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,319.31 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $246.27 | 6 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $246.27 | 6 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $233.05 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $219.04 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $219.04 | 4 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $217.17 | 4 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $193.92 | 1 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $180.00 | 4 | 2025 |
Source payment records
|
|||||
| FLOWSAVER Normalized: flowsaver |
Device | Stryker Corporation | $156.10 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $155.55 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $155.55 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $155.55 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $150.98 | 3 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $142.80 | 3 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $134.19 | 15 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $129.19 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $127.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $117.26 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $77.50 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $76.75 | 4 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $73.23 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $73.23 | 2 | 2025 |
Source payment records
|
|||||
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $66.61 | 2 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $66.61 | 2 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $66.61 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $63.92 | 2 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $54.45 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $40.08 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Stent Graft Normalized: gore tag conformable thoracic stent graft |
Device | W. L. Gore & Associates, Inc. | $36.40 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $27.83 | 3 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| RESTOREFLOW Normalized: restoreflow |
Device | LeMaitre Vascular, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 59 | 29 |
| Cephalexin | Cephalexin | 13 | 11 |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,319.31 · 82 records | Stryker Corporation | AFFINITY, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AZUR CX DETACHABLE, Altius, Alto Abdominal Stent Graft System, CGuard Prime Carotid Stent System, CLOTTRIEVER BOLD CATHETER, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, Cohealyx, Crosser IQ, ENROUTE Transcarotid Neuroprotection System, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWSAVER, FLOWTRIEVER CATHETER, S, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE TAG Conformable Thoracic Stent Graft, GRAFIX PL, General - Atherectomy, IGT Devices Undivided, INNOVAMATRIX AC, IV Other, Indigo System, Integra, Integra Dermal Regeneration Template, Kerecis GraftGuide, Kerecis SurgiClose, LUTONIX Drug Coated Balloon, LYMPHA PRESS OPTIMAL PLUS(US) BT, Labosys, NOVOSORB BTM, PCD-51 731A (US) - White, PCD-52 737A (US) White, PRIMATRIX, PURAPLY WOUND MATRIX, Permeaderm, RESTOREFLOW, RUBY Coil, Recell, Restrata Wound Matrix, RotarexS 6 F x 135 cm, STRAVIX, ZILVER PTX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error